Please use this identifier to cite or link to this item:
|Title:||Botulinum toxin for upper limb cerebral palsy in children : evidence of efficacy and rationale for its use|
|Authors:||Azzopardi, Ernest A.|
Boyce, Dean E.
|Keywords:||Botulinum toxin -- Therapeutic use|
Botulinum toxin -- Side effects
Pain -- Treatment
|Publisher:||British Association of Plastic Reconstructive & Aesthetic Surgeons|
|Citation:||Azzopardi, E. A., & Boyce, D. E. (2019). Botulinum toxin for upper limb cerebral palsy in children : evidence of efficacy and rationale for its use. British Association of Plastic Reconstructive & Aesthetic Surgeons Winter Conference. Monaco: Royal College of Surgeons in England.|
|Abstract:||Background: Cerebral Palsy (CP) affects 0.2% of live births worldwide. Its resultant motor spasticity contributes to reduced upper limb function and a significantly reduced quality of life. Intramuscular injection of Botulinum Toxin A (BoNT-A) for upper limb CP is gaining popularity. However, its use for paediatric patients remains off-license and off-label. The administering surgeon therefore requires an up to date, evidence-based rationale to justify its use in an NHS setting, and advise on best-practice.|
|Appears in Collections:||Scholarly Works - FacM&SAna|
Items in OAR@UM are protected by copyright, with all rights reserved, unless otherwise indicated.